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In BRAF V600Emelanoma patients, RAF inhibitor treatment causes aMEK-inhibitor-sensitive, RAF-inhibitor-
resistant adaptive reactivation of ERK signaling. In clinical trials combining MEK and RAF inhibitors, thera-
peutic efficacy was modestly enhanced, suggesting the utility of inhibiting feedback-reactivated pathways.
Strategies for optimally inhibiting ERK signaling should be explored.The RAS/RAF/MEK/ERK pathway is dys-
regulated in almost all melanomas, mostly
due to activating mutations of BRAF or
NRAS or genetic changes causing loss
of NF1 function. Inhibitors of this pathway
have attracted a great deal of interest as
therapeutics. Potent (>80%) inhibition of
ERK signaling is required for significant
antitumor activity (Bollag et al., 2010).
MEK inhibitors have only modest clinical
activity in these patients (Flaherty et al.,
2012), perhaps because MEK inhibitors
suppress ERK signaling in both tumor
and normal cells; thus, on-target toxicities
limit the doses that can be administered
safely. This is not the case for RAF inhibi-
tors. They selectively inhibit ERK signaling
inmelanomas that express themost com-
mon RAF mutations (BRAF V600E/K),
whereas they induce ERK signaling in
normal and other tumor cells. This para-doxical activation of ERK is due to trans-
activation of wild-type RAF dimers when
one protomer of the dimer is bound to
drug (Poulikakos et al., 2010). In most
melanomas, BRAF V600E exists as
a monomer and is inhibited potently by
drug (Poulikakos et al., 2011).
Tumor- and mutation-specific inhibition
of ERK signaling by RAF inhibitors ex-
plains their broad therapeutic index. The
two Food and Drug Administration (FDA)-
approved RAF inhibitors—vemurafenib
anddabrafenib—havehigh response rates
in BRAF-mutated melanomas (approxi-
mately 50%), and vemurafenib improves
patient survival (Chapman et al., 2011;
Hauschild et al., 2012). However, anti-
tumor responses are usually temporary
and rarely complete. Treatment is also
complicated by toxicities attributable to
ERK activation in skin, including hypertro-phic skin changes and induction of kera-
toacanthomas and cutaneous squamous
cell carcinomas.
Inhibition of ERK signaling in BRAF
mutant tumors relieves ERK-dependent
feedback inhibition of receptor signaling
and of CRAF kinase activity. This results
in induction of RAS activation, formation
of RAF inhibitor-resistant, wild-type CRAF
dimers, and a rebound in ERK activation
that is sensitive to MEK inhibitors but
resistant to RAF inhibitors (Lito et al.,
2012). These results imply that the adap-
tive rebound in ERK signaling in tumors
exposed toRAF inhibitorsmay reduce their
clinical effectiveness. Addition of MEK in-
hibitors might therefore reduce the toxicity
(by antagonizing the paradoxical activation
of ERK in normal cells) and enhance the
effectiveness of RAF inhibitors (by further
inhibiting ERK in tumor cells). Two suchovember 10, 2014 ª2014 Elsevier Inc. 603
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Previewstrials have recently been reported that test
this hypothesis (Larkin et al., 2014; Long
et al., 2014). In each, previously untreated
patients with metastatic BRAF-mutated
melanoma were randomly assigned to
treatment with RAF inhibitor monotherapy
or a RAF inhibitor plus a MEK inhibitor.
In the trial of Long and colleagues, pa-
tients were treated with either dabrafenib
alone (150 mg twice daily) or dabrafenib
combined with trametinib (2 mg daily).
Earlier in the year, theFDAgrantedacceler-
ated approval of this combination based
on a small randomized phase II trial in
which, compared to dabrafenib monother-
apy, the combination doubled the com-
plete response rate (4% versus 9%) and
improvedmedianprogression-free survival
by 16 weeks (5.8 to 9.4 months) (Flaherty
et al., 2012). The results of the trial by
Long and colleagues, designed as a large
(423 patients) confirmatory study, were
disappointing. The combination did not
increase the rate of complete responses
and prolonged median progression-free
survival by only 2 weeks. Follow-up has
been too short to assess overall survival,
althoughthere isa trend in favorof thecom-
bination. The addition of the MEK inhibitor
decreased toxicities thought to result from
RAF-inhibitor-induced activation of the
ERK pathway (hyperkeratosis and squa-
mous cell carcinomas of the skin). How-
ever, other toxicities, such as fever and
diarrhea, were more common in patients
treatedwith thecombination and led todis-
continuance of treatment in 9% of patients
on the combination arm compared to 5%
receiving dabrafenib monotherapy.
The other phase III trial, Larkin et al.
(2014), randomly assigned 495 previously
untreated patients with BRAF-mutated
melanoma to a different RAF inhibitor (ve-
murafenib 960 mg twice daily) alone or in
combination with a different MEK inhibitor
(cobemetinib 60 mg daily for 21 days fol-
lowed by 7 days off). The vemurafenib/
cobimetinib combination induced more
complete responses than vemurafenib
alone (10% versus 4%). The combination
also improved median progression-free
survival (9.9 months versus 6.2 months),
a difference of 16 weeks. As with the trial
by Long and colleagues, the RAF/MEK in-
hibitor combination was associated with
less skin toxicity but with more fever,
diarrhea, and retinal changes (mostly
asymptomatic). Also, consistent with the604 Cancer Cell 26, November 10, 2014 ª20study by Long et al., a trend toward
improved survival was observed with the
combination.
In each of the two trials, treatment with
the MEK and RAF inhibitor combination
was associated with a median progres-
sion-free survival of 9–10 months. In
both trials, this was statistically superior
to the RAF inhibitor alone, although in
the case of dabrafenib/trametinib, there
was only a 2week difference. It is possible
that at the doses used, a higher degree of
MEK inhibitionwas obtainedwith cobime-
tinib than with trametinib, thus resulting in
the greater improvement over RAF inhibi-
tor monotherapy. In any event, drug resis-
tance remains a major clinical problem
even with the addition of a MEK inhibitor.
The mechanisms of resistance were not
reported in these papers, although other
recent work shows that resistance to
combined inhibition of MEK and RAS is
typically associated with ERK reactivation
similar to what is observed with RAF in-
hibitor monotherapy (Wagle et al., 2014).
Many questions remain unanswered
concerning the mechanisms underlying
these clinical responses and how to
enhance them. The results reflect an
improvement in outcome, but median
time to progression is still less than 1
year. The best RAF and MEK inhibitors (or
potentially ERK inhibitors) to use and the
optimal dosage and schedules remain un-
known. The pharmacologic and biochem-
ical properties of these drugs vary, and it
has been recently shown that the anti-
tumor effects of some MEK inhibitors are
less sensitive to feedback reactivation of
CRAF. Intermittent therapy with a RAF in-
hibitor has also recently been shown to
be more effective than daily scheduling in
treating BRAF V600E tumors in a PDX
model (Das Thakur et al., 2013) and could
allow higher doses of MEK inhibitor.
These trials showed that the toxicity of
RAF inhibitors caused by paradoxical
pathway activation in normal cells can
be blocked by MEK inhibition. Other
RAF inhibitor toxicities, such as fever
and gastrointestinal toxicities, were more
frequent in patients receiving combination
therapy. It is not known whether these
toxicities can be minimized by altering
the dosing of each drug to balance the
inhibition and paradoxical activation of
ERK induced by the MEK and RAF inhibi-
tors, respectively, or whether some of14 Elsevier Inc.these are off-target toxicities. MEK inhib-
itors have other class-specific reversible
toxicities, such as rash, retinopathy, and
myocyte damage. There is reason to sus-
pect that pathway activation by RAF in-
hibitors in these tissues could reduce
these toxicities, allowing for the adminis-
tration of higher doses of MEK inhibitors.
Understanding the mechanisms by which
this combination works, using pharmaco-
logic principles and drugs with superior
biochemical properties to maximize
pathway inhibition and minimize or inhibit
adaptive responses, could lead to consid-
erable improvement in the therapeutic
effects of this regimen.
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